|
|
Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2002-08-2455.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2003, Vol. 102, No. 7, pp. 2338-2344
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells
Tanja Maier,
Adrian Tun-Kyi,
Anatoli Tassis,
Karl-Peter Jungius,
Günter Burg,
Reinhard Dummer, and
Frank O. Nestle
From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland.
Cutaneous T-cell lymphoma (CTCL) is a lymphoproliferative skin disease with limited therapeutic options. Ten CTCL patients were treated with once-weekly intranodal injection of 1 x 106 mature monocyte-derived dendritic cells (DCs) pulsed with 100 µg/mL tumor lysate protein equivalent and keyhole limpet hemocyanin (50 µg/mL). Tumor-specific delayed-type hypersensitivity (DTH) reactions developed in 8 of 8 patients challenged with tumor-lysate-pulsed DCs and in 3 of 8 patients challenged with tumor lysate alone. Three of 5 patients showed significant tumor-lysate-specific increases of in vitro peripheral blood lymphocyte proliferation coinciding with increased interferon- (IFN-) production. Five of 10 (50%) patients had objective responses. Four patients had partial responses (PRs). Two are still in PR, and the other 2 patients had a mean PR duration of 10.5 months. One patient had a complete response (CR) for 19 months that is ongoing. The remaining 5 patients had progressive disease. In the 5 responder patients, 6.8 ± 1.4 vaccinations were necessary to induce an objective clinical response. Response was associated with low tumor burden. Continuation of vaccinations with new tumor lysate derived from progressive lesions reinduced treatment responses in 2 patients in PR. Selected patients had massive infiltration of CD8+ and TIA+ cytotoxic T cells at the site of regressing lesions and molecular remission after therapy. Intranodal injection of autologous tumor-lysate-pulsed DCs is well-tolerated and achieves immunologic and objective clinical responses in selected CTCL patients. (Blood. 2003;102:2338-2344)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Tackling T-cell tumors
- H. Kim Lyerly
Blood 2003 102: 2313.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology,
January 1, 2007;
2007(1):
243 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano, T. Kobayashi, S. Yoshida, T. Abe, M. Narita, M. Takahashi, et al.
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
Clin. Cancer Res.,
June 1, 2005;
11(11):
4160 - 4167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cloosen, M. Thio, A. Vanclee, E. B. M. van Leeuwen, B. L. M. G. Senden-Gijsbers, E. B. H. Oving, W. T. V. Germeraad, and G. M. J. Bos
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo
Int. Immunol.,
November 1, 2004;
16(11):
1561 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. O'Neill, S. Adams, and N. Bhardwaj
Manipulating dendritic cell biology for the active immunotherapy of cancer
Blood,
October 15, 2004;
104(8):
2235 - 2246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni and P. Brossart
Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status
Stem Cells,
July 1, 2004;
22(4):
501 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
